Search for: "Par Pharmaceutical Inc."
Results 1 - 20 of 38
Sorted by Relevance | Sort by Date
23 Jul, 2007 9:13 pm
By Sherri Oslick -- Ortho-McNeil, Inc. announced late last week that it has settled its lawsuit against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc. and Kali Laboratories, Inc., over the patent covering Ortho's Ultracet® (tramadol hydrochloride and acetaminophen, used to
treat acute pain). As part of the...
6 Mar 7:03 am
... conjunction with California's Attorney General, launched its latest challenge to reverse payment settlements in the pharmaceutical
industry, Fed. Trade Comm'n et al. v. Watson Pharm., Inc. et al., 09-cv-00598 (AHM) ("Watson"). In a press release announcing the action ... million in U.S. sales in 2007. The
complaint also names generic pharmaceutical companies Watson Pharmaceuticals, Par
Pharmaceuticals and Paddock Laboratories. Pursuant to the regulatory framework of the Drug Price ...
16 Oct, 2006 7:58 pm
... new lawsuits. New lawsuits filed: Biovail Laboratories filed a new lawsuit against Andrx Pharmaceuticals over Andrx's attempt to market generic Cardizem. Novartis sued
Par ... settled patent litigation with generic drug makers Par Pharmaceutical Cos. and Watson Pharmaceuticals Inc. over Solvay's AndroGel drug product. AndroGel, a treatment ... , 2015, which is five years
before Solvay's patent on AndroGel expires. Par will co-promote AndroGel for $10 million a year beginning in 2006 and will.be allowed ...
2 Jul, 2007 9:44 pm
By Donald Zuhn -- Valeant Pharmaceuticals International announced today (July 2, 2007) that it has settled its patent infringement suit with Kali Laboratories, Inc. (which
was acquired by Par Pharmaceutical in June of 2004). Valeant's patent infringement action involved
Diastat®, which Valeant markets as the only FDA-approved at-home acute treatment...
29 May 1:10 pm
The Federal Court recently issued its judgment in NPS Pharmaceuticals, Inc v. Biofarma, Société Par Actions Simplifiée. This case
was an appeal by NPS from a decision of the Trade-marks Opposition Board, which had refused NPS's application to register PREOS, on the basis that it was confusing with Biofarma's prior
application for PROTOS. Both marks were associated with osteoporosis medications. The Board analyzed the facts ...
20 Mar 2:05 am
... . 299, 305-06 (Cal. App. 1986); Fogo v. Cutter Laboratories, Inc., 137 Cal. Rptr. 417, 422-23 (Cal. App. 1977); Carmichael v. ... 416 F.2d 417, 426 (2d Cir. 1969). District
of Columbia: McNeil Pharmaceutical v. Hawkins, 686 A.2d 567, 578 (D.C. 1996). Florida: E ... (5th Cir. 1988). Maine: Porter v. Pfizer Hospital
Products Group, Inc., 783 F.Supp. 1466, 1475 (D. Me. 1992). Maryland: Gourdine v ... , 770 (W.D. Va. 1980). Washington: Laisure-Radke v. Par Pharmaceutical, Inc., 426 F.Supp.2d 1163, 1172-73 (W.D. ...
6 Jan, 2008 10:28 am
For the second time in about two weeks, drug manufacturer AstraZeneca Pharmaceuticals LP has sued Mylan Pharmaceuticals Inc., alleging infringement by Mylan on its
patent for cholesterol drug Crestor. Here is the complaint, which was filed ... No. 1:07-CV-00805. The other generics manufacturers named (in separate complaints) are Sun
Pharmaceuticals Industries, Ltd., Sandoz Inc., Par Pharmaceutical Inc., Apotex
Inc., Aurobindo Pharma Ltd., and Cobalt Pharmaceuticals Inc. In other Mylan litigation, ...
5 Apr, 2007 5:39 am
... *12-13 (Vt. Oct. 27, 2006); McNellis, supra; Laisure-Radke v. Par Pharmaceutical, Inc.,
2006 WL 901657, at *4 (W.D. Wash. Mar. 29, 2006); Caraker ... they discover new evidence of a particular risk following the approval of the original label); Perry v. Novartis
Pharmaceuticals Corp., 456 F. Supp.2d 678, 685-86 (E.D. Pa. 2006 ... is a holistic endeavor." U.S. National Bank v. Independent Insurance Agents of America, Inc., 508 U.S.
439, 455 (1993). What a statute or regulation means is often "clarified" by ...
22 Jan 2:06 am
... 6 (N.D.N.Y. Jul. 19, 2006); Laisure-Radke v. Par Pharmaceutical, Inc., 2006 WL 901657, at
*4 (W.D. Wash. Mar. 29, 2006); ... were a substantial factor in bringing about his or her injury." Rutherford v. Owens-Illinois, Inc., 16 Cal.4th 953, 968 (1997). Identifying the
actual manufacturer is not difficult in ... a generic drug should be better off - with an extra cause of action against a non-manufacturing pharmaceutical company - than an identical plaintiff who took a pioneer drug. Cf. Ramirez, 6 Cal.4th ...
17 Jan, 2008 7:55 am
... s no conflict with FDA regulation, this argument goes, because under that regulation, the defendant pharmaceutical company could always add
or strengthen its warning without prior FDA approval - ... courts have accepted this §314.70(c)(6)(iii) argument and ruled that pharmaceutical
defendants should have unilaterally strengthened suicide warnings for antidepressants - despite the FDA having ... .2d 964, 968 (D. Neb. 2006); Laisure-Radke v. Par Pharmaceutical, Inc., 2006 WL 901657, at *4-5 (W.D. Wash. Mar. ...
7 Oct 9:59 pm
... for the District of New Jersey has signed off on Sanofi-Aventis' settlement agreement with Sun Pharmaceutical Industries Ltd. despite the
fact that Sanofi failed to exchange all relevant signature pages. The agreement ... a colon cancer drug manufactured and marketed by Sanofi (see "Biotech/Pharma Docket," July 14, 2009).
Sanofi originally filed suit against Sun, Sandoz, Actavis Inc., and Par Pharmaceutical
Inc., among other generic manufacturers, in June 2007, accusing them of infringing Sanofi's ...
9 Mar 7:00 am
... May and Samuel Rudin Family Foundation Sonnenschein Nath & Rosenthal, LLP Emily Tisch Sussman UBS Alyssa Zeller and Adam Sheer Bingham McCutchen LLP Boehringer Ingelheim Brooke
and Tom Gordon Cushman & Wakefield Mitchell & Titus Prudential San Francisco AIDS Foundation Strativa Pharmaceuticals A Division of PAR Pharmaceutical, Inc. Tibotec
19 Apr 7:13 pm
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic
monitoring. Par Pharmaceutical, Inc. v. Novartis Pharmaceuticals Corp. et al.
2:09-cv-01592; filed April 16, 2009 in the Eastern District of Pennsylvania Declaratory judgment of invalidity and non-infringement of U.S. Patent Nos. 5,463,116 ("Crystals of ...
18 Oct, 2008 8:19 am
In the Hatch-Waxman area, Pozen, Inc. announced Par Pharmaceutical Inc. has filed an
application with the Food and Drug Administration [FDA] to make a generic version of Treximet, a migraine treatment Pozen developed with GlaxoSmithKline PLC, and shares of Pozen shed
nearly 28 percent of their value on 17 Oct. 08
13 May, 2007 5:18 pm
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic
monitoring. Purdue Pharma Products LP et. al. v. Par Pharmaceuticals Inc. et. al.1:07-cv-00255; filed May 9, 2007 in the
District...
28 Oct, 2007 9:50 pm
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic
monitoring. Purdue Pharma Products LP et al. v. Par Pharmaceutical Inc. et al. 1:07-cv-00666;
filed October 24, 2007 in the...
10 Mar, 2008 1:10 pm
... trial court as error: applying the standards identified in Daubert v. Merrell Dow Pharmaceuticals, Inc., supra, and concluding that the Masons' expert witnesses, Dr.
Ziem and ... perform a judicial function by construing a law, and offends [Art. I, Sec. II, Par. III] of the Constitution of this State, and is
void.' [Cit.]" Id. In Calhoun v. State ... judicial function, . .. and constitutes a potential destruction of the judicial process." Northside Manor, Inc. v. Vann, 219 Ga. 298,
301 (133 SE2d 32) (1963 ...
27 Feb 5:00 am
... patent infringement following Teva's Para IV certification as part of ANDA for generic Integrilin: Millennium Pharmaceuticals Inc. et al. v. Teva Parenteral Medicines
... 's earlier covenant to sue (Law360) (Hal Wegner) Lotrel (Amlodipine) - US: Par and Novartis settle Lotrel lawsuit (Patent Docs)
(GenericsWeb) Lovenox (Enoxaparin ... ANDA to manufacture generic Seroquel (Patent Docs) Skelaxin (Metaxalone) - US: King Pharmaceuticals' patents on Skelaxin invalidated by
District Court E D New York (Patent ...
18 Oct 5:42 pm
... district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay's branded testosterone-replacement
drug AndroGel, a prescription pharmaceutical with annual sales of more than $400 million. "At a time [...]... Senate Bill Would Prevent Reverse
Pharma PaymentsThe Patent Docs are reporting that on ...
2 Nov, 2007 11:00 pm
... in a patent dispute over Prilosec OTC: (IP Law 360), (Generic Pharmaceuticals), Cobalt Pharmaceuticals Inc. is seeking U.S. regulatory approval to make and sell
a generic version of Astrazeneca PLC's cholesterol drug Crestor: (IP Law 360), Apple seeks revocation ... total of 25 defendants for infringing their patents for flash memory:
(IPFactor), (Philip Brooks), Par Pharmaceuticals appetite stimulant patent (for liquids containing megestrol acetate) still invalid as
lacking ...
Search on: Blawgs.FM | BlawgSearch Google Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!